CN104645319A - Collagen oral preparation - Google Patents
Collagen oral preparation Download PDFInfo
- Publication number
- CN104645319A CN104645319A CN201310625411.5A CN201310625411A CN104645319A CN 104645319 A CN104645319 A CN 104645319A CN 201310625411 A CN201310625411 A CN 201310625411A CN 104645319 A CN104645319 A CN 104645319A
- Authority
- CN
- China
- Prior art keywords
- preparation
- starch
- collagen type
- collagen
- pharmaceutic adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a biochemical medicine preparation, and discloses a collagen oral preparation II and a preparation method of the collagen oral preparation II. The collagen oral preparation is prepared by the following steps: swelling animal cartilage in low-concentration acetic acid; digesting with enzyme, separating and purifying to obtain collagen II by a salting-out method; and preparing the oral preparation together with pharmaceutical auxiliary materials. The preparation provided by the invention can be applied to treatment of rheumatoid arthritis osteoarthritis and multiple recurrent chondritis.
Description
The invention belongs to biochemical drug.Be specifically related to a kind of collagen oral preparation.
Rheumatoid arthritis is a kind of systemic autoimmune disease based on chronic polyarthritis.Existing medicine for treatment is roughly divided into two classes: a class is non-specific symptomatic treatment medicine, such as aspirin, adrenocortical hormone and NSAID (non-steroidal anti-inflammatory drug) etc., but the side effect of this kind of medicine mainly causes gastritis, even gastrorrhagia, heart failure, liver, kidney patient are cautious use of; Another kind of is the antirheumatic improving the state of an illness, such as thio phenyl fruit acid gold sodium, penicillamine, Radix Tripterygii Wilfordii, chloroquine etc., but this kind of preparation is apart from outside gastrointestinal reaction, also with albuminuria and fall the symptom such as leukocyte or thrombocytopenia, the cause of disease of rheumatoid arthritis is failed to understand so far, patient articular is red and swollen, pain deforming, and pathological characters to be that collagen fiber are degraded and joint cartilage.METHOTREXATE (methotrexate), CYCLOSPORINA (cyclosporin A) and AZATHIOPRIN E (sulfur azoles Piao purine) have been used to treatment rheumatic arthritis and relapsing polychondritis.But they are nonspecific immunosuppressive drugs, have cytotoxicity, long-term taking can reduce the immunologic function of patient.In the last few years, people be devoted to use Chinese medicine " with dirty control dirty " principle, treatment rheumatic arthritis and relapsing polychondritis is given in animal cartilage application.But because only adopting simple decocting method effectively can not extract principle active component in cartilage, with and have impact on curative effect.
The main component of chondroprotein is collagen, containing forming triple helix structure by three protein chains in collagen protein.Collagen protein in cartilage is mainly II collagen type and on a small quantity IV, VI collagen type.II collagen type is made up of three identical protein chains, and IV type and VI collagen type are made up of three different protein chains, and these three kinds of collagen protein form chondrigen fiber together.Collagen fiber are except maintaining except the mechanical strength of cartilage, and also combined by the extracellular matrix receptor of its RGD aminoacid sequence and cell surface, the signal transmitted ensure that existence, the growth and differ entiation of chondrocyte.In cartilage, collagen fiber by hyaluronic acid and chondroitin sulfate embed, therefore the solubility of chondrigen is extremely low.
The object of the invention is to overcome above weak point, develop a kind of chondrigen preparation of solubility.The present inventor utilizes protease digestion to make chondrigen fiber change the tropocollagen molecule of solubility into, and enzymology cartilage is applied to the treatment to rheumatic arthritis and relapsing polychondritis.
The invention provides a kind of collagen oral preparation.Said preparation forms using II collagen type as main active and pharmaceutic adjuvant, and they can by being 0.0001%-99.9999% containing the II collagen type as active component and containing the composition that pharmaceutic adjuvant is any proportioning formation 100% of 99.9999%-0.0001%.
Claims (3)
1. an II collagen type preparation, it is characterized in that said preparation forms using II collagen type as active component and pharmaceutic adjuvant, they can by being 0.0001%-99.9999% containing the II collagen type as active component and containing the composition that pharmaceutic adjuvant is any proportioning formation 100% of 99.9999%-0.0001%.
2. a preparation method for the strong spoken parts in traditional operas formulation of II Collagen Type VI as claimed in claim 1, is characterized in that the method gets animal cartilage, and add the normal saline homogenate of 5-10 times amount, collected by centrifugation is heavy, with absolute ethanol washing, centrifugal.Collect, precipitation, precipitation is dissolved in the solution of sodium acetate PH < 4 of 0.01-0.8mol/L, w/v is 1: 60, low temperature (0-10 DEG C) is placed and is spent the night, add the trypsin that pepsin that concentration is 0.01-4 mg/ml or concentration are 0.01-50 mg/ml, low temperature (0-10 DEG C) is placed and is spent the night, centrifugal, get supernatant, add sodium chloride 0.5-4 mole, placement is spent the night, centrifugal, collecting precipitation, be dissolved in acetum or the 1-5% extender of 20-50 times amount Ph < 5, namely II Collagen Type VI raw material is made after lyophilizing, then according to a conventional method this raw material and pharmaceutic adjuvant are mixed with oral tablet chaste tree, capsule, powder, granule, water preparation, the various preparation such as lyophilized preparation.
3. II collagen type oral formulations according to claim 1 and 2, is characterized in that wherein said pharmaceutic adjuvant is that the binding agent of routine is as starch, hydroxypropyl starch, modified starch, pregelatinized Starch, dextrin, Icing Sugar, Microcrystalline cellulose, gelatine size, PVP rubber cement; Disintegrating agent is carboxymethyl starch sodium, starch, microcrystalline Cellulose; Lubricant is modified starch, microcrystalline Cellulose, micropowder silica gel, aluminium hydroxide; Extender is starch and derivant, cellulose and derivant, inorganic compound, organic salt and hexose acids or pentitol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310625411.5A CN104645319A (en) | 2013-11-21 | 2013-11-21 | Collagen oral preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310625411.5A CN104645319A (en) | 2013-11-21 | 2013-11-21 | Collagen oral preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104645319A true CN104645319A (en) | 2015-05-27 |
Family
ID=53237285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310625411.5A Pending CN104645319A (en) | 2013-11-21 | 2013-11-21 | Collagen oral preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104645319A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106944A (en) * | 2018-10-10 | 2019-01-01 | 安徽盛美诺生物技术有限公司 | It is a kind of prevent and treat osteoarthritis composition and its application |
-
2013
- 2013-11-21 CN CN201310625411.5A patent/CN104645319A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106944A (en) * | 2018-10-10 | 2019-01-01 | 安徽盛美诺生物技术有限公司 | It is a kind of prevent and treat osteoarthritis composition and its application |
| CN109106944B (en) * | 2018-10-10 | 2021-12-07 | 北京盛美诺生物技术有限公司 | Composition for preventing and treating osteoarthritis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100584343C (en) | Medicine health-care usage of globefish I collagen extraction and preparing process thereof | |
| CN102698254B (en) | Composition for increasing bone mineral density, preparation agent containing same, and preparation method of same | |
| Patel et al. | Anti-urolithiatic activity of ethanolic extract of seeds of Benincasa hispida (Thumb) | |
| WO2002100417A2 (en) | Use of glycosaminoglycans for the treatment of hiv-associated nephropathy | |
| CN107961366A (en) | Application of the sunflower small-molecular peptides in anti-trioxypurine dissolves tophus repairing kidney functions | |
| NO343552B1 (en) | Compositions for the treatment of chronic degenerative inflammatory conditions | |
| CN104645319A (en) | Collagen oral preparation | |
| WO2021092979A1 (en) | Low-molecular-weight holothurian glycosaminoglycan and use thereof | |
| ES2239582T3 (en) | A COMPOSITION TO TREAT DEGENERATIVE ARTICULAR DISEASES. | |
| CN100425251C (en) | Pharmaceutical composition for treating bone diseases and method for preparing the same | |
| JP2007523925A (en) | New therapeutic uses for a group of sulfated polysaccharides | |
| WO2023186181A1 (en) | Application of mulberry extract in preparation of drug for treating ulcerative colitis | |
| CN104448038B (en) | Preparation process of calcium chondroitin sulfate salt | |
| CN100464745C (en) | Medication composition of acetyl cysteine or its pharmaceutical salt and asarin | |
| JP2006298791A (en) | Medicine for oral administration, health food or nutrient chemical composition containing glycosaminoglycan or its salt | |
| CN109793751B (en) | Application of arabinoxylan sulfonate in preparation of medicine for treating osteoarthritis | |
| CN104448037B (en) | A kind of preparation technology of chondroitin sulfate potassium salt | |
| CN1185338A (en) | Collagen oral preparation and preparing method thereof | |
| CN101428036A (en) | Uses of modified polysaccharide rich ingalactose in medicament for treating inflammatory bowel diseases | |
| CN1137681C (en) | Asiaticoside antisticking film and its preparation method | |
| US10092540B2 (en) | Method of treatment of a mucopolysaccharidosis | |
| CN111375002A (en) | Pharmaceutical composition for treating hyperuricemia and preparation method and application thereof | |
| KR20210010383A (en) | Use of bio-transformed bear bile powder in preparation of anti-inflammatory drugs | |
| Li et al. | Alimentary tract of Schistosoma | |
| CN114340658B (en) | Composition for preventing or treating uric acid diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150527 |